NFSG
TOVX icon

Newbridge Financial Services Group’s Theriva Biologics TOVX Stock Holding History

Newbridge Financial Services Group’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1 Hold
5
– – ﹤0.01% 1224
2026
Q1 		$1 Hold
5
– – ﹤0.01% 1179
2025
Q4 		$1 Buy
+5
New +$1 ﹤0.01% 1175

Other funds holding TOVX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Newbridge Financial Services Group's TOVX Position: Q2 2026 in Review

Newbridge Financial Services Group held its Theriva Biologics (TOVX) position steady in Q2 2026 at 5 shares worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #1224.

Newbridge Financial Services Group first reported a position in TOVX in Q4 2025 and has held it in 3 quarters since. 26 funds tracked by Wall St. Rank hold TOVX as of Q2 2026.

  • Newbridge Financial Services Group held 5 shares of Theriva Biologics worth $1 as of Q2 2026.
  • Newbridge Financial Services Group left its Theriva Biologics share count unchanged in Q2 2026.
  • Theriva Biologics made up ﹤0.01% of Newbridge Financial Services Group's portfolio in Q2 2026, its #1224 holding.
  • Newbridge Financial Services Group first reported a position in Theriva Biologics in Q4 2025 and has held it in 3 quarters since.
  • 26 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2026.

Based on Newbridge Financial Services Group's 13F filing for Q2 2026, filed 14 Aug 2026.